OCUGEN, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
OCUGEN, INC. (OCGN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- OCUGEN, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was -$8.00K.
- OCUGEN, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was -$37.00K.
- OCUGEN, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.31M, a 1169.90% increase from fiscal 2024.
- OCUGEN, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $103.00K, a 81.99% decline from fiscal 2023.
- OCUGEN, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $572.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | -$8.00K derived: sum of 3 quarters · filed 2026-08-06 | -$45.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-08 | -$8.00K derived: sum of 2 quarters · filed 2026-05-08 | -$45.00K derived: sum of 3 quarters · filed 2026-05-08 | $880.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$45.00K derived: sum of 2 quarters · filed 2026-03-04 | $880.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.31M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $888.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.32M 10-Q · filed 2025-11-05 | $1.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $925.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.35M 10-Q · filed 2026-08-06 | $1.35M derived: sum of 3 quarters · filed 2026-08-06 | $1.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $428.00K 10-Q · filed 2026-05-08 | $428.00K derived: sum of 2 quarters · filed 2026-05-08 | $428.00K derived: sum of 3 quarters · filed 2026-05-08 | $531.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $0.00 derived: sum of 2 quarters · filed 2026-03-04 | $103.00K derived: sum of 3 quarters · filed 2026-03-04 | $103.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $103.00K derived: sum of 2 quarters · filed 2025-11-05 | $103.00K 10-Q · filed 2025-11-05 | $675.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $103.00K 10-Q · filed 2025-08-04 | $675.00K derived: sum of 3 quarters · filed 2025-08-04 | $675.00K derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $572.00K derived: sum of 2 quarters · filed 2025-05-09 | $572.00K derived: sum of 3 quarters · filed 2025-05-09 | |
| 2023-12-31 | $572.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $572.00K derived: sum of 2 quarters · filed 2025-03-05 | $572.00K 10-K · filed 2025-03-05 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 8-K/A 6 month · filed 2019-11-12 | -$6.39M derived: sum of 2 quarters · filed 2019-11-12 | $245.97K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$6.39M derived: 8-K/A 6 month − 10-Q 3 month · filed 2019-10-07 | $245.97K 8-K/A · filed 2019-10-07 | ||
| 2019-03-31 | $6.63M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |